Overview

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Status:
COMPLETED
Trial end date:
2025-06-16
Target enrollment:
Participant gender:
Summary
To evaluate the safety, efficacy, pharmacokinetic (PK) characteristics and antiviral activity of different doses of Deuterium Hydrobromide for suspension in the treatment of respiratory syncytial virus infection in infants.
Phase:
PHASE2
Details
Lead Sponsor:
Vigonvita Life Sciences
Treatments:
GS-621763
Suspensions